Evaluation of QIAreach QuantiFERON-TB lateral-flow nanoparticle fluorescence assay for TB infection diagnosis among TB household contacts in three high-burden settings
PLOS One · 2025
DOI: 10.1371/journal.pone.0332125 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Thobani Ntshiqa und 22 weiteren Autor:innen. Beteiligte Einrichtung: The Aurum Institute, Johannesburg, South Africa. Hauptthemen laut MEDLINE: Tuberculosis, Interferon-gamma Release Tests, Nanoparticles. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The European and Developing Countries Clinical Trials Partnership.
Abstract (Originalsprache)
Background
Tuberculosis infection (TBI) testing, and treatment are fundamental to achieve TB elimination. TBI testing among close or household contacts (HHCs) has been limited, in part due to perceived complexity and high operational cost. We evaluated the performance of a new near-patient and field-based QIAreach QuantiFERON-TB (QIAreach) against QuantiFERON-TB-Gold-Plus (QFT-Plus) among HHCs of people with TB.
Methods
A cross-sectional study was conducted from July 2021 to September 2022 in Lesotho, South Africa and Tanzania. Blood samples were collected from HHCs for paired QFT-Plus and QIAreach processing, testing and interpretation. To evaluate the performance of QIAreach against QFT-Plus as a reference, we determined the: i) prevalence of TBI, ii) total concordance using Cohen’s Kappa, iii) predictors of discordant results using logistic regression, and iv) relationship between time to results and interferon-gamma (IFN-γ) response levels using linear correlation.
Results
Out of 964 enrolled HHCs, 464 had paired results, of whom 64.9% (302/465) were female with a cohort median age of 27 years (interquartile range (IQR): 13–45). Overall, 50.9% (236/464) tested positive on QFT-Plus, while 57.1% (265/464) were positive on QIAreach assay. Total concordance between QFT-Plus and QIAreach was 78.4% [353/450, 95% confidence interval (CI): 74.4–82.2, Cohen’s Kappa: 0.5627, p < 0.001]. Discordance between assays was 23.9% (111/464) and was associated with Lesotho site (adjusted odds ratio 2.70, 95%CI: 1.48–4.92, p = 0.001). HHCs with higher IFN-γ response (QFT-Plus) (≥0.35 IU.ml- l ) had a shorter time to results on QIAreach. In addition, a strong negative correlation between QIAreach time to results and IFN-γ response (QFT-Plus) levels (R = −0.64, 95% CI: −0.87 to −0.41, p < 0.001) was observed.
Conclusion
QIAreach demonstrated a moderate concordance against QFT-Plus among HHCs in three high-burden countries. Further work is needed to understand and improve its usability in high TB and low resource settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The Aurum Institute, Johannesburg, South Africa.
- School of Public Health, University of the Witwatersrand, Johannesburg, South Africa.
- Institute for Global Health, University College London, United Kingdom.
- Jhpiego, Baltimore, Maryland, United States of America.
- Mbeya Medical Research Centre, National Institute for Medical Research, Tanzania.
- Jhpiego, Monitoring, Evaluation and Research Division, Maseru, Lesotho.
ORCID-Profile: Thobani Ntshiqa, Stacie Stender, Issa Sabi, Manthomeng Matete, Don Mudzengi, Kavindhran Velen, Yohhei Hamada
Förderung
- The European and Developing Countries Clinical Trials Partnership
Zitieren
APA
Ntshiqa, T., Fasanmi, A., Nagudi, J., Tsope, L., Copas, A., Stender, S., Sabi, I., Ntinginya, E. N., Lalashowi, J., Matete, M., Budiaki, L., Mahlalela, M., Kisinda, A., Mudzengi, D., Minja, L. T., Chirwa, T., Lönnroth, K., Niemann, S., Dreyer, V., …, & Rangaka, M. (2025). Evaluation of QIAreach QuantiFERON-TB lateral-flow nanoparticle fluorescence assay for TB infection diagnosis among TB household contacts in three high-burden settings. PLOS One. https://doi.org/10.1371/journal.pone.0332125
Vancouver
Ntshiqa T, Fasanmi A, Nagudi J, Tsope L, Copas A, Stender S, et al. Evaluation of QIAreach QuantiFERON-TB lateral-flow nanoparticle fluorescence assay for TB infection diagnosis among TB household contacts in three high-burden settings. PLOS One. 2025. doi:10.1371/journal.pone.0332125
BibTeX
@article{Ntshiqa2025,
author = {Ntshiqa, Thobani and Fasanmi, Akinlolu and Nagudi, Jeniffer and Tsope, Lindiwe and Copas, Andrew and Stender, Stacie and Sabi, Issa and Ntinginya, Elias Nyanda and Lalashowi, Julieth and Matete, Manthomeng and Budiaki, Lula and Mahlalela, Malebo and Kisinda, Abisai and Mudzengi, Don and Minja, Lilian Tina and Chirwa, Tobias and Lönnroth, Knut and Niemann, Stefan and Dreyer, Viola and Charalambous, Salome and Velen, Kavindhran and Hamada, Yohhei and Rangaka, Molebogeng},
title = {Evaluation of QIAreach QuantiFERON-TB lateral-flow nanoparticle fluorescence assay for TB infection diagnosis among TB household contacts in three high-burden settings},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0332125}
}
EUVIMED